Clinical trials: HAART-treated
HIV Infection, HAART-treated
Dolutegravir + Rilpivirine Switch Study (DORISS)
The primary objective of the study is to evaluate the capacity of Dolutegravir + Rilpivirine vs. continued triple combination HAART to maintain plasma HIV RNA ≤ 50 copies/ml throughout 24 weeks in patients with plasma HIV RNA ≤…
- Conditions
- HIV Infection, HAART-treated, Virologically Controlled
- Trial name
- DORISS (NCT02069834)
- Testing
- Arm 1 (intervention), Arm 2 (control)
- Where
- 25 sites in France
- Sponsor
- Nantes University Hospital
HIV Infection, Osteopenia
Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis
Advances in HAART have been a huge success story in the management of HIV infection. However, serious metabolic complications including osteoporosis and bone fractures are increasingly been seen with HAART, and the responsible…
- Conditions
- HIV Infection, Osteopenia, Osteoporosis
- Trial name
- OPG-2 (NCT01020045)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and…
- Trial name
- NCT00002392
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockefeller University
HIV Infections
Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects
Racivir ® (RCV) is an experimental drug which means it is not approved for use by the United States Food and Drug Administration (FDA), but it can be used in research studies like this one.
- Trial name
- NCT00121979
- Testing
- Racivir, a non-nucleoside reverse transcriptase inhibitor
- Where
- 6 sites in United States, Argentina and 2 more
- Volunteers
- 60 people
- Sponsor
- Pharmasset
HIV Infections
HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)
This study will investigate low-level viral loads in HIV-infected patients taking highly active antiretroviral therapy (HAART). Although HAART reduces viral levels and restores immune function to some degree, it does not cure HIV…
- Trial name
- NCT00043641
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day…
- Trial name
- NCT00294372
- Testing
- BILR 355 BS
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
HIV
Structured Treatment Interruption for HIV Patients With Virologic Failure
The purpose of this study is to assess the virologic impact of switching treatment-experienced HIV-infected patients with virologic failure to a salvage regimen with or without a 12 week STI prior to the switch.
- Trial name
- NCT00188851
- Testing
- therapeutic management strategy
- Volunteers
- 196 people
- Sponsor
- University Health Network, Toronto
HIV Infection
Strategic Timing of Antiretroviral Treatment
Objectives: To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high…
- Trial name
- START (NCT00867048)
- Testing
- All licensed antiretroviral medications
- Where
- 218 sites in United States, Argentina and 34 more
- Volunteers
- 4,688 people
- Sponsor
- University of Minnesota
HIV Infections
Lopinavir/r Monotherapy as Maintenance Therapy After Long Term Viral Suppression
1. Objectives Primary To investigate the possibility of maintaining virological suppression of HIV in infected patients, switching them to LPV/r as the only antiretroviral agent To assess the immunological response in patients…
- Trial name
- NCT00160849
- Testing
- Lopinavir/r
- Where
- 2 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- Universidade Federal do Rio de Janeiro
HIV Infections
Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication
The purpose of this study is to see if the amount of stem cells (cells that can develop into many kinds of cells) in the blood before anti-HIV drugs are taken can predict if the immune system will become stronger after anti-HIV…
- Trial name
- NCT00006578
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- 5 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial
A roll-over observational study (ISS T-003 EF-UP) is being conducted to extend the follow-up of the volunteers of the ISS T-003 trial in order to evaluate the persistence of vaccine immunogenicity as well as of the immunological…
- Trial name
- ISST-003EF-UP (NCT02712489)
- Testing
- No intervention
- Where
- South Africa
- Volunteers
- 179 people
- Sponsor
- Barbara Ensoli, MD, PhD
HIV, Cognitive Therapy
Cognitive Therapy in Patients Failing ART
Highly active antiretroviral therapy (HAART) has been the greatest achievement to control the HIV/AIDS epidemic in the world. HAART has been shown to reduce virus replication to undetectable levels and to favor the recovery of…
- Trial name
- CognitiveTher (NCT03751046)
- Testing
- Trial-Based Cognitive Therapy, Control group. Standard healthcare.
- Where
- Colombia
- Volunteers
- 100 people
- Sponsor
- Fundação Bahiana de Infectologia
Acquired Immunodeficiency Syndrome
Longitudinal Study of HAART, Social Networks, & Adherence
Our study is a randomized controlled trial that aims to evaluate the effectiveness of modified directly observed therapy (mDOT) to (1) increase both short and long term adherence to HAART treatment, and (2) improve clinical…
- Trial name
- NCT00272220
- Testing
- modified directly observed therapy (mDOT)
- Where
- Mozambique
- Volunteers
- 350 people
- Sponsor
- University of Washington
HIV Infections
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients
HIV-1-infected patients who have been treated with anti-HIV drugs for a long time may have weakened immune responses to HIV. The DNA-based vaccine in this study is designed to boost the immune system's responses against many…
- Trial name
- NCT00052182
- Testing
- EP HIV-1090
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis B
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV) in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV drugs for 24 weeks, then stop taking…
- Trial name
- NCT00051090
- Testing
- Telbivudine, Lamivudine, Efavirenz
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children
The primary objective of this study is to assess the efficacy of switching to tenofovir disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining virologic suppression in HIV-1 infected children.
- Trial name
- NCT00528957
- Testing
- Tenofovir DF, Zidovudine, Stavudine
- Where
- 9 sites in United States, Panama and 1 more
- Volunteers
- 97 people
- Sponsor
- Gilead Sciences
HIV Infection
Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects
The present study is designed as a prospective observational study directed at evaluating the frequency, magnitude, quality and persistence (primary endpoint) of the anti-Tat immune response in highly active antiretroviral…
- Trial name
- ISS OBS T-002 (NCT01024556)
- Where
- 10 sites in Italy
- Volunteers
- 142 people
- Sponsor
- Barbara Ensoli, MD
HIV Infections
Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy
The purpose of this study is to assess the safety and efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) plus a genotype-guided optimized background regimen (OBR) compared to placebo plus OBR in the treatment of human…
- Trial name
- NCT00352053
- Testing
- Tenofovir DF
- Where
- 18 sites in Brazil, Panama
- Volunteers
- 87 people
- Sponsor
- Gilead Sciences
HIV Infections
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
The purpose of this study is to compare the anti-HIV efficacy, safety and effect of serum lipids of two boosted protease inhibitor-based HAART regimens (ARV/RTV v.
- Trial name
- NCT00135395
- Testing
- Atazanavir+ritonavir, Lopinavir+ritonavir
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb